Physiological iron homeostasis

Physiological iron homeostasis is a tightly regulated systemic process essential for maintaining iron levels within a narrow therapeutic window to support erythropoiesis and cellular metabolism while avoiding oxidative damage (StatPearls, 2023). The central regulatory mechanism is the Hepcidin-Ferroportin axis, where the liver-secreted hormone hepcidin controls the systemic entry of iron by inducing the internalization and degradation of the iron exporter ferroportin (NIH, 2023). Dysregulation of this system is a primary driver of several major diseases, including iron deficiency anemia, anemia of chronic disease (ACD), and hereditary hemochromatosis (Nature Reviews Disease Primers, 2020). Therapeutic strategies targeting this system range from direct iron replacement and chelation therapy to novel molecular approaches such as hepcidin mimetics and ferroportin inhibitors (PubMed, 2022). For biotech analysts, this target represents a broad physiological pathway rather than a single molecule, with multiple druggable nodes including HAMP (hepcidin), SLC40A1 (ferroportin), and TFRC (transferrin receptor) (UniProt, 2024). Understanding the interplay between these components is critical for developing treatments for disorders of iron distribution and utilization.

Other names

Iron metabolismIron regulationSystemic iron homeostasisIron ion homeostasis

Modulation of systemic iron levels via supplementation, chelation of excess iron, or regulation of the Hepcidin-Ferroportin axis to control iron absorption and recycling.